The 2014 Garrod Lecture: EUCAST – are we heading towards international agreement?
Open Access
- 18 June 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 70 (9), 2427-2439
- https://doi.org/10.1093/jac/dkv145
Abstract
Antimicrobial susceptibility testing with phenotypic methods is based on the measurement of the MIC (mg/L) and breakpoints to categorize bacteria and fungi as susceptible, intermediate or resistant. Phenotypic antimicrobial susceptibility testing requires an agreement on breakpoints and a rigorous standardization of methods and materials. Requirements for defining breakpoints include a definition of doses and dose intervals, information on MIC distributions for the target organisms, definitions of the highest MIC for organisms devoid of phenotypically expressed resistance (the epidemiological cut-off) and information on resistance mechanisms, pharmacokinetics, pharmacodynamics and clinical outcome in trials. In 2001, the breakpoint committees of France, Germany, Norway, Sweden, the Netherlands and the UK were tasked with developing European breakpoints under the umbrella of EUCAST, organized by ESCMID and later also by ECDC. Breakpoints for previously established antibacterial and antifungal agents in Europe have now been harmonized. With the EMA, EUCAST has since 2006 determined breakpoints for new agents. All breakpoints are freely available on the EUCAST web site; these are used in semi-automated antimicrobial susceptibility testing devices and have been employed since 2010 in a EUCAST disc diffusion method. They have been or are now being implemented in most countries inside Europe and many countries outside it. Everything needed to perform and interpret antimicrobial susceptibility testing is freely available from the EUCAST web site, as are aggregated MIC distributions based on more than 26 000 distributions.Keywords
This publication has 15 references indexed in Scilit:
- EUCAST expert rules in antimicrobial susceptibility testingClinical Microbiology & Infection, 2013
- Genotyping using whole-genome sequencing is a realistic alternative to surveillance based on phenotypic antimicrobial susceptibility testingJournal of Antimicrobial Chemotherapy, 2012
- The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approachClinical Microbiology & Infection, 2012
- Normalized Resistance Interpretation as a Tool for Establishing Epidemiological MIC Susceptibility BreakpointsJournal of Clinical Microbiology, 2010
- Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target SpeciesAntimicrobial Agents and Chemotherapy, 2009
- Breakpoints for intravenously used cephalosporins in Enterobacteriaceae—EUCAST and CLSI breakpointsClinical Microbiology & Infection, 2008
- Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off valuesClinical Microbiology & Infection, 2006
- European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteriaJournal of Antimicrobial Chemotherapy, 2003
- A new method for normalized interpretation of antimicrobial resistance from disk test results for comparative purposesClinical Microbiology & Infection, 2003
- Antibiotic Susceptibility Testing by a Standardized Single Disk MethodAmerican Journal of Clinical Pathology, 1966